2023
Tumor treatment by pHLIP-targeted antigen delivery
DuPont M, Visca H, Moshnikova A, Engelman D, Reshetnyak Y, Andreev O. Tumor treatment by pHLIP-targeted antigen delivery. Frontiers In Bioengineering And Biotechnology 2023, 10: 1082290. PMID: 36686229, PMCID: PMC9853002, DOI: 10.3389/fbioe.2022.1082290.Peer-Reviewed Original ResearchAnti-HA antibodiesAntigen deliveryHigh titersTumor cellsTriple-negative breast tumorsCancer cellsDifferent vaccination schemesNegative breast tumorsHA epitopeAntigen therapyImmunized miceImmune cellsNeo-antigensT cellsSignificant tumorsVaccination schemeViral infectionTherapeutic efficacyBreast tumorsHepatic clearanceImmune systemMelanoma tumorsTumorsPeptide epitopesAdjuvant
2022
Eradication of tumors and development of anti-cancer immunity using STINGa targeted by pHLIP
Moshnikova A, DuPont M, Visca H, Engelman D, Andreev O, Reshetnyak Y. Eradication of tumors and development of anti-cancer immunity using STINGa targeted by pHLIP. Frontiers In Oncology 2022, 12: 1023959. PMID: 36330464, PMCID: PMC9622777, DOI: 10.3389/fonc.2022.1023959.Peer-Reviewed Original ResearchTumor-associated macrophagesCancer-associated fibroblastsSTING agonistsT cellsTumor microenvironmentDendritic cellsCT26 tumorsM2-type tumor-associated macrophagesAnti-cancer immunityTumor-free miceEradication of tumorsActivation of cytokinesNovel STING agonistSuppressor cellsSingle doseImmune cellsIntratumoral hemorrhageTherapeutic effectTumor stromaImmune memoryNude miceAdditional injectionTumorsCancer cellsMice